Literature DB >> 14676132

The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.

Christoph Jung1, Monica Motwani, Jeremy Kortmansky, Francis M Sirotnak, Yuhong She, Mithat Gonen, Adriana Haimovitz-Friedman, Gary K Schwartz.   

Abstract

PURPOSE: Flavopiridol is a cyclin-dependent kinase inhibitor currently under development by the National Cancer Institute both as a single agent and in combination with chemotherapy. There have been numerous reports that flavopiridol potently enhances the induction of apoptosis by chemotherapy. However, the effect of flavopiridol on radiotherapy (RT)-induced apoptosis has been largely untested. RT has become the cornerstone of adjuvant treatment of colorectal and gastric cancer. In view of this, we elected to evaluate the effect of flavopiridol on potentiating RT-induced apoptosis in the human colon cancer cell line HCT-116 and the gastric cancer cell line MKN-74. EXPERIMENTAL
DESIGN: The efficacy of combination of gamma-irradiation and flavopiridol was tested in vitro in MKN-74 and HCT-116 cells and correlated to changes in p21 expression. HCT-116 cells were also established as tumors in nude mice and treated with gamma-irradiation and flavopiridol either as single agents or in sequential combinations such that flavopiridol was either given 7 h before, concomitantly, or 3 and 7 h after gamma-irradiation.
RESULTS: Flavopiridol significantly enhanced the induction of apoptosis by gamma-irradiation in both cell lines as measured by quantitative fluorescent microscopy, caspase-3 activation, poly(ADP-ribose) polymerase cleavage, and cytochrome c release. To achieve the best effect, it was important to expose the tumor cells to gamma-irradiation before the flavopiridol. This sequence dependence was confirmed in vivo. When gamma-irradiation was administered 7 h before flavopiridol, 42% of the tumor-bearing animals were rendered disease free, compared with no animals treated with either gamma-irradiation or flavopiridol alone. Examination of the p21 status of HCT-116 and MKN-74 cells, after treatment with sequential gamma-irradiation and flavopiridol, indicated a loss of p21 protein expression. Loss of p21 was mainly due to cleavage by caspases. HCT-116 cells that lack p21 (p21(-/-)) also exhibited sensitization to gamma-irradiation and showed an even greater enhancement of gamma-irradiation-induced apoptosis by flavopiridol when compared with the parental HCT-116 cells.
CONCLUSIONS: These studies indicate that gamma-irradiation followed by flavopiridol enhances apoptosis and yields significantly increased tumor regressions and cures that are not achievable with radiation alone. These results indicate that flavopiridol can potently enhance the effect of gamma-radiation both in vitro and in vivo and may provide a new means to treat patients with locally advanced gastrointestinal cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14676132

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

Review 1.  Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.

Authors:  L Pignataro; G Sambataro; D Pagani; G Pruneri
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

Review 2.  Targeted therapies for gastric cancer: current status.

Authors:  Jaclyn Yoong; Michael Michael; Trevor Leong
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

3.  Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.

Authors:  Michael F T Koehler; Philippe Bergeron; Elizabeth M Blackwood; Krista Bowman; Kevin R Clark; Ron Firestein; James R Kiefer; Klaus Maskos; Mark L McCleland; Linda Orren; Laurent Salphati; Steve Schmidt; Elisabeth V Schneider; Jiansheng Wu; Maureen H Beresini
Journal:  ACS Med Chem Lett       Date:  2016-01-06       Impact factor: 4.345

4.  Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.

Authors:  Philippe Bergeron; Michael F T Koehler; Elizabeth M Blackwood; Krista Bowman; Kevin Clark; Ron Firestein; James R Kiefer; Klaus Maskos; Mark L McCleland; Linda Orren; Sreemathy Ramaswamy; Laurent Salphati; Steve Schmidt; Elisabeth V Schneider; Jiansheng Wu; Maureen Beresini
Journal:  ACS Med Chem Lett       Date:  2016-04-05       Impact factor: 4.345

5.  Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.

Authors:  Frank Mayer; Sandra Mueller; Elke Malenke; M Kuczyk; Jörg T Hartmann; Carsten Bokemeyer
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

6.  p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.

Authors:  Carwyn Davies; Linda A Hogarth; Philipp A Dietrich; Petra S Bachmann; Karen L Mackenzie; Andrew G Hall; Richard B Lock
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

7.  Enhancement of radiation effects by flavopiridol in uterine cervix cancer cells.

Authors:  Suzy Kim; Hong-Gyun Wu; Jin Hee Shin; Hye Jin Park; In Ah Kim; Il Han Kim
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

8.  Zebrafish as a model system to screen radiation modifiers.

Authors:  Misun Hwang; Cha Yong; Luigi Moretti; Bo Lu
Journal:  Curr Genomics       Date:  2007-09       Impact factor: 2.236

9.  Prevention and Treatment of Colorectal Cancer by Natural Agents From Mother Nature.

Authors:  Bharat Aggarwal; Sahdeo Prasad; Bokyung Sung; Sunil Krishnan; Sushovan Guha
Journal:  Curr Colorectal Cancer Rep       Date:  2013-03-01

10.  Down-expression of tumor protein p53-induced nuclear protein 1 in human gastric cancer.

Authors:  Pei-Hong Jiang; Yoshiharu Motoo; Stéphane Garcia; Juan Lucio Iovanna; Marie-Josèphe Pébusque; Norio Sawabu
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.